Patrick Henno is a PhD graduated from the French University of Compiègne (1985).
In 1997, he founded a company named MAbgène which was bought by LFB in 2011 (now LFB Biomanufacturing), focused on the production of proteins and cell therapy developments as a CMO.
Headquarters and production unit have been settled in Alès and produced biomolecules according to GMP regulations.
He joined CELLforCURE as the executive general manager, from 2011 to 2013.
In 2013, he became a co-founder of EMERCell SAS, company focused on the development of immunotherapy projects and the implementation of the first pharmaceutical development steps.